Innehållet nedan modereras inte i förväg och omfattas därmed inte av webbplatsens utgivningsbevis.
Dela sida
Sponsrat innehåll

Therapeutic Targets for Alzheimer's Disease

New Alzheimer's Therapeutics: Pioneering Approaches to Tackle a Growing Concern

Alzheimer's disease (AD) is a complex neurological disorder that significantly impacts the aging population. Molecular biomarkers play pivotal roles in AD's pathological processes, offering potential targets for therapeutic interventions. Sino Biological is at the forefront of Alzheimer's research, offering recombinant Alzheimer's biomarkers for drug discovery and novel therapeutics development.

Featured Products for Alzheimer's Drug Targets

Sino Biological has developed a panel of high-quality recombinant proteins for Alzheimer's drug targets, including APP, Tau, BACE1, ApoE, GLP1R, NGF, BDNF, GSK3B, CASP9, CLU, AGER, DPYSL2, and PNMT with high purity (HPLC-verified) and high bioactivity. These proteins are trusted by users as indicated by citations in top-tier journals. The antibodies against Alzheimer's targets are also available with a variety of applications, such as ELISA, IHC-P, FCM, WB, and IP. 

Learn more about Alzheimer's drug targets

Download Alzheimer's disease target poster to gain more valuable insights.

Find out more drug targets in different research fields.

Sino Biological Europe GmbH
Düsseldorfer Str. 40
65760 Eschborn
VAT nummer: DE323950120


Sino Biological Europe GmbH

Sänd till en kollega